Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 2
2005 2
2006 3
2007 11
2008 9
2009 5
2010 8
2011 6
2012 9
2013 10
2014 10
2015 6
2016 6
2017 8
2018 7
2019 7
2020 11
2021 8
2022 10
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL. Armand P, et al. Among authors: gulbas z. J Clin Oncol. 2019 Dec 1;37(34):3291-3299. doi: 10.1200/JCO.19.01389. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609651 Free PMC article. Clinical Trial.
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, Kalyon H, Akay OM, Deveci B, Bekoz H, Sevindik OG, Toptas T, Yilmaz F, Koyun D, Alkis N, Alacacioglu I, Sonmez M, Yavasoglu I, Tombak A, Mehtap O, Kurnaz F, Yuce OK, Karakus V, Turgut M, Kurekci DD, Ayer M, Keklik M, Buyuktas D, Ozbalak M, Ferhanoglu B. Birtas Atesoglu E, et al. Among authors: gulbas z. Hematol Oncol. 2023 Oct;41(4):663-673. doi: 10.1002/hon.3174. Epub 2023 May 22. Hematol Oncol. 2023. PMID: 37211991
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P. Zinzani PL, et al. Among authors: gulbas z. Blood. 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340. Blood. 2023. PMID: 37130017 Free PMC article. Clinical Trial.
Pembrolizumab in relapsed or refractory Richter syndrome.
Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, Svoboda J, Stathis A, Chatterjee A, Orlowski R, Marinello P, Christian B. Armand P, et al. Among authors: gulbas z. Br J Haematol. 2020 Jul;190(2):e117-e120. doi: 10.1111/bjh.16762. Epub 2020 Jun 16. Br J Haematol. 2020. PMID: 32544980 Free PMC article. Clinical Trial. No abstract available.
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Ye Y, Labopin M, Chen J, Gulbas Z, Zhang X, Koc Y, Blaise D, Ciceri F, Polge E, Houhou M, Li L, Luo Y, Wu D, Huang H, Mohty M, Gorin NC. Ye Y, et al. Among authors: gulbas z. J Hematol Oncol. 2023 Mar 18;16(1):25. doi: 10.1186/s13045-023-01421-9. J Hematol Oncol. 2023. PMID: 36934271 Free PMC article.
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
Penack O, Abouqateb M, Peczynski C, Boreland W, Gülbas Z, Gedde-Dahl T, Castilla-Llorente C, Kröger N, Eder M, Rambaldi A, Bonifazi F, Blau IW, Stelljes M, Dreger P, Moiseev I, Schoemans H, Koenecke C, Peric Z. Penack O, et al. Among authors: gulbas z. Blood Cancer J. 2024 Mar 15;14(1):45. doi: 10.1038/s41408-024-01032-8. Blood Cancer J. 2024. PMID: 38485723 Free PMC article.
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
Beksac M, Aydin Y, Goker H, Turgut M, Besisik SK, Cagirgan S, Tuglular T, Vural F, Yagci M, Alacacioglu I, Aytan P, Goksoy HS, Gulbas Z, Gunes AK, Gurkan E, Hacioglu SK, Karti SS, Kaynar L, Ozdogu H, Paydas S, Solmaz S, Sonmez M, Tekgunduz E, Yildirim R, Ilhan O. Beksac M, et al. Among authors: gulbas z. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e474-e484. doi: 10.1016/j.clml.2020.02.017. Epub 2020 Mar 7. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32482539 Free article. Review.
135 results